Combination therapy in hypertension: An update

被引:58
|
作者
Kalra, Sanjay [1 ]
Kalra, Bharti [2 ]
Agrawal, Navneet [3 ]
机构
[1] Bharti Hosp, Dept Endocrinol, Karnal, India
[2] Bharti Hosp, Dept Gynaecol, Karnal, India
[3] GR Med Coll, Dept Med, Gwalior, India
来源
DIABETOLOGY & METABOLIC SYNDROME | 2010年 / 2卷
关键词
RENIN-ANGIOTENSIN SYSTEM; CONVERTING-ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; NONDIABETIC RENAL-DISEASE; CHRONIC HEART-FAILURE; BLOOD-PRESSURE; TELMISARTAN-AMLODIPINE; CARDIOVASCULAR EVENTS; BETA-BLOCKERS; DOUBLE-BLIND;
D O I
10.1186/1758-5996-2-44
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Meticulous control of blood pressure is required in patients with hypertension to produce the maximum reduction in clinical cardiovascular end points, especially in patients with comorbidities like diabetes mellitus where more aggressive blood pressure lowering might be beneficial. Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy may be theoretically favored by the fact that multiple factors contribute to hypertension, and achieving control of blood pressure with single agent acting through one particular mechanism may not be possible. Regimens can either be fixed dose combinations or drugs added sequentially one after other. Combining the drugs makes them available in a convenient dosing format, lower the dose of individual component, thus, reducing the side effects and improving compliance. Classes of antihypertensive agents which have been commonly used are angiotensin receptor blockers, thiazide diuretics, beta and alpha blockers, calcium antagonists and angiotensin-converting enzyme inhibitors. Thiazide diuretics and calcium channel blockers are effective, as well as combinations that include renin-angiotensin-aldosterone system blockers, in reducing BP. The majority of currently available fixed-dose combinations are diuretic-based. Combinations may be individualized according to the presence of comorbidities like diabetes mellitus, chronic renal failure, heart failure, thyroid disorders and for special population groups like elderly and pregnant females.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
    Narita, Keisuke
    Hoshide, Satoshi
    Kario, Kazuomi
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [22] Obstructive Sleep Apnea and Hypertension An Update
    Konecny, Tomas
    Kara, Tomas
    Somers, Virend K.
    HYPERTENSION, 2014, 63 (02) : 203 - 209
  • [23] Vitamin D and hypertension: an update and review
    Tamez, Hector
    Thadhani, Ravi I.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2012, 21 (05): : 492 - 499
  • [24] Combination Therapy for Pulmonary Arterial Hypertension
    Roman Broto, Antonio
    Monforte Torres, Victor
    ARCHIVOS DE BRONCONEUMOLOGIA, 2009, 45 (01): : 36 - 40
  • [25] Sevikar®: combination therapy for the treatment of hypertension
    Eduardo Pimenta
    Advances in Therapy, 2009, 26 : 1 - 11
  • [27] Pulmonary Hypertension: Role of Combination Therapy
    Meis, Tobias
    Behr, Juergen
    CURRENT VASCULAR PHARMACOLOGY, 2011, 9 (04) : 457 - 464
  • [28] Optimizing Management of Hypertension With Combination Therapy Considerations for the Nurse Practitioner
    Roberts, Mary Ellen
    Epstein, Benjamin J.
    JOURNAL OF CARDIOVASCULAR NURSING, 2009, 24 (05) : 380 - 389
  • [29] Extemporaneous combination therapy with nebivolol/ramipril for the treatment of hypertension: a real-world evidence study in Europe
    Desideri, Giovambattista
    Pegoraro, Valeria
    Cipelli, Riccardo
    Ripellino, Claudio
    Miroddi, Marco
    Meto, Suada
    Gori, Mario
    Fabrizzi, Paolo
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (07) : 1093 - 1102
  • [30] ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients
    Presta, Vivianne
    Figliuzzi, Ilaria
    Citoni, Barbara
    Gallo, Giovanna
    Battistoni, Allegra
    Tocci, Giuliano
    Volpe, Massimo
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (03) : 255 - 262